1. Generics Bulletin
  2. >>Leadership

Zentiva Enters A New Phase With Saltofte As CEO

New Chief Takes Over From Nick Haggar, Who Moves To Advisory Committee

 
• By Dave Wallace

Zentiva has announced that Steffen Saltofte will become CEO of the privately-owned generics firm, replacing Nick Haggar who has led the company for over four years.

Wooden Blocks Management CEO Appointment
Saltofte has been named as Zentiva CEO from 2 May • Source: Shutterstock

Zentiva will be under new management from the start of next month, after the privately-owned Czech Republic-based company announced that former Acino chief Steffen Saltofte would join the firm to succeed Nick Haggar as CEO from 2 May.

Having been appointed to lead Acino in mid-2018 (Also see "Acino names Saltofte as its chief executive" - Generics Bulletin, 22 June, 2018.), Saltofte served as CEO of the firm until 2022, shortly after Acino was acquired by the state-backed Abu Dhabi Developmental Holding Company, or ADQ, from its former private-equity owners Nordic Capital and Avista Capital Partners

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.